Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future Proofing HTA: How Systems Must Adapt To AI And Digital Medtech

Executive Summary

Artificial intelligence is a major advancement in medtech due to its ability to rapidly adapt, improve and learn. However, value assessment models must also reform to keep up with this technology in the medtech space, an HTA expert told Medtech Insight.

You may also be interested in...



‘Project Glass Box’ - UK Reveals Roadmap For AI Medtech Regulation

The MHRA recently announced plans to review and reform how medical devices with AI or software components are to be regulated in the UK. Its new roadmap sheds light on how, exactly, it will deliver on these ambitions.

UK Ethnic Bias In Medtech Review To Probe AI Algorithms And Regulatory Gaps

There is potential for ethnic and socio-economic bias in medical device design, funding allocation and regulatory guidelines, according to the UK’s Department of Health and Social Care (DHSC), which has commissioned a review to uncover the extent of the problem.

UK’s NICE Outlines Standards That AI and Data-Driven Medtech Should Meet For NHS Uptake

NICE, the body that produces health technology assessment guidance for England and Wales, has earlier this month introduced updates to its evidence standards guidance for developers of digital technologies based on artificial intelligence (AI) and on adaptive algorithms.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT146042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel